tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
PremiumRatingsOptimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
8d ago
Immunovant Stockholders Approve Key Governance Decisions
Premium
Company Announcements
Immunovant Stockholders Approve Key Governance Decisions
9d ago
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
Premium
Ratings
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
22d ago
Immunovant Reports Progress and Financial Results
PremiumCompany AnnouncementsImmunovant Reports Progress and Financial Results
25d ago
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
Premium
Ratings
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
26d ago
Immunovant price target lowered to $57 from $58 at Citi
Premium
The Fly
Immunovant price target lowered to $57 from $58 at Citi
26d ago
Immunovant 3M share Block Trade priced at $17.85
PremiumThe FlyImmunovant 3M share Block Trade priced at $17.85
1M ago
Immunovant 3M share Block Trade; price range $17.85-$18.00
Premium
The Fly
Immunovant 3M share Block Trade; price range $17.85-$18.00
1M ago
Immunovant resumed with a Neutral at Goldman Sachs
Premium
The Fly
Immunovant resumed with a Neutral at Goldman Sachs
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100